Business

Modern aims for autumn release for omicron, variant-specific COVID-19 vaccine boosters




NEWYou can now listen to Fox News articles!

Moderna has set a broad timeline for delivering a variant-specific COVID-19 vaccine enhancer just days after asking the Food and Drug Administration (FDA) for permission to use the vaccine in children.

“We announced a couple of weeks ago a new, variant-specific booster that we have tested, and we have an additional candidate, our main candidate, in testing now that I think will be even more superior,” said Moderna Chief Medical. Paul Burton during a performance on “Face the Nation”.

“We are confident that by the fall of this year we should have large quantities of the new booster vaccine that will protect against omicron and other variants, and truly protect Americans and people around the world as we enter the fall of 2022.”[ads1];

COVID VACCINES FOR AMERICA’S YOUNGEST CHILDREN: FDA ANNOUNCES JUNE MEETINGS

The FDA set a deadline of June for drug manufacturers to submit a formula for variant-specific vaccines. Doses of modified vaccines could cost the US government between $ 5 and $ 12 billion, The New York Times reported.

The modern timeline can allow them to meet this deadline, if the testing goes smoothly and does not reveal any problems in the current wording.

CHINA’S ZERO COVID ‘RESTRICTIONS UNDERSTAND 1. MAY HOLIDAY TRAVEL

Modern also recently submitted FDA applications for the youngest children, 6 years or younger.

“The data in the study is complete, and what we usually do is package the data electronically for the FDA so they can conduct their own assessments, their own analyzes,” Burton said. “It will go in by May 9, but they have the data they need now to begin.”

CHARLIE CRIST SAYS HE IS “OPEN” TO MASK MANDATE, WHICH SETS UP COVID AS A KEY QUESTION IN RACE AGAINST DESANTIS

The vaccine is 37% effective in children aged 2 to 5 and 51% effective in children under 2 years of age. The lower efficiency, Burton claimed, is due to the strong virulence of the omicron variant.

“What it means for parents or caregivers is that if they give the Moderna vaccine to these young children, they will basically halve the risk of the children getting symptomatic COVID,” “I know that 50% is often lower than what we” are used to to see with our vaccine, but that’s because this study was conducted under omicron. ”

CLICK HERE TO GET THE FOX NEWS APP

“When we look at the data in the UK that was released last week … right there we see vaccine efficacy of 50%, but when we look at vaccine efficacy against hospitalization it is 89-95%, so that’s why I think we can be very reassured and very confident in this result. “

Right now, only children 5 years of age or older can be vaccinated in the United States using rival Pfizer’s vaccine.

Fox News’ Julia Musto contributed to this report.



Source link

Back to top button